Labeling, characterization, and in vivo localization of a new 90Y-based phosphonate chelate 2,3-dicarboxypropane-1,1-diphosphonic acid for the treatment of bone metastases: Comparison with 99mTc–DPD complex

The goal of this investigation was to examine the possibilities for yttrium-90-labeling of the 2,3-dicarboxypropane-1,1-diphosphonic acid (DPD), which is currently labeled with technetium-99m and as a 99mTc–DPD clinically used as bone imaging agent. Analysis of the complex enclosed the radiochemical quality control methods, biodistribution studies, as well as the determination of pharmacokinetic parameters. The biological behavior of complexes 90Y–DPD, 99mTc–DPD and 90Y-labeled DPD-kit formulation [90Y–(Sn)–DPD] in animal model was compared. The labeling conditions were standardized to give the maximum yield, which ranged between 93% and 98%. The examined 90Y complex could be easily prepared, with an outstanding yield and was also found to be very stable for at least 10 h after 90Y-labeling. Protein binding value was 4.6 ± 0.7% for 90Y–DPD complex and the complex possess a hydrophilic character. The satisfactory results of 90Y–DPD biodistribution in healthy test animals were obtained; the uptake in the bone was 11–13% ID/g after 24 h depending on the pH value during the preparation. With high skeletal uptake, a minimum uptake in soft tissues and rapid blood clearance the 90Y–DPD complex proved to be an excellent candidate for targeting tumor therapy.

Figure optionsDownload as PowerPoint slide